These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35226630)

  • 41. Spectrum and antibiotic resistance in community- and hospital-acquired urinary tract infections among adults: Experience from a large tertiary care center in a developing country.
    Herbawi A; Abu Taha A; Aiesh BM; Sabateen A; Zyoud SH
    Urologia; 2024 May; 91(2):394-402. PubMed ID: 38488375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive factors of urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children: a prospective Tunisian study.
    Boussetta A; Kharbach N; Abdellatif A; Karray A; Jellouli M; Gargah T
    Tunis Med; 2023 Feb; 101(2):285-291. PubMed ID: 37682274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibiotic resistance patterns of pediatric community-acquired urinary tract infections in a tertiary care center in Jeddah, Saudi Arabia.
    Alsubaie MA; Alsuheili AZ; Aljehani MN; Alothman AA; Alzahrani AS; Mohammedfadel HA; Alshehry MA; Alnajjar AA
    J Infect Dev Ctries; 2023 Oct; 17(10):1430-1435. PubMed ID: 37956373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors of urinary tract infection caused by extended spectrum β-lactamase-producing Escherichia coli in emergency department.
    Lee H; Han SB; Kim JH; Kang S; Durey A
    Am J Emerg Med; 2018 Sep; 36(9):1608-1612. PubMed ID: 29373168
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Cho SY; Choi SM; Park SH; Lee DG; Choi JH; Yoo JH
    Korean J Intern Med; 2016 Jan; 31(1):156-61. PubMed ID: 26767869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015.
    Chervet D; Lortholary O; Zahar JR; Dufougeray A; Pilmis B; Partouche H
    Med Mal Infect; 2018 May; 48(3):188-192. PubMed ID: 29054298
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and risk factors of extended-spectrum beta-lactamase producing E. coli causing urinary tract infections in Iceland during 2012-2021.
    Halldórsdóttir AM; Hrafnkelsson B; Einarsdóttir K; Kristinsson KG
    Eur J Clin Microbiol Infect Dis; 2024 Sep; 43(9):1689-1697. PubMed ID: 38935227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigation of risk factors for community-acquired urinary tract infections caused by extended-spectrum beta-lactamase
    Koksal E; Tulek N; Sonmezer MC; Temocin F; Bulut C; Hatipoglu C; Erdinc FS; Ertem G
    Investig Clin Urol; 2019 Jan; 60(1):46-53. PubMed ID: 30637361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging extended-spectrum β-lactamase-producing Klebsiella pneumoniae causing community-onset urinary tract infections: a case-control-control study.
    Boix-Palop L; Xercavins M; Badía C; Obradors M; Riera M; Freixas N; Pérez J; Rodríguez-Carballeira M; Garau J; Calbo E
    Int J Antimicrob Agents; 2017 Aug; 50(2):197-202. PubMed ID: 28552471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extended-spectrum β-lactamase-producing bacteria causing community-acquired urinary tract infections in children.
    Megged O
    Pediatr Nephrol; 2014 Sep; 29(9):1583-7. PubMed ID: 24705795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
    Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
    Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Influence of Non-E. Coli or Extended-Spectrum β-Lactamase-Producing Bacterial Growth on the Follow-Up Procedure of Infants with the First Febrile Urinary Tract Infection.
    Kavruk M; Soyaltın E; Erfidan G; Arslansoyu Çamlar S; Alaygut D; Mutlubaş F; Yılmaz N; Kasap Demir B
    Indian J Pediatr; 2023 Jul; 90(7):677-682. PubMed ID: 35727527
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extended-spectrum β-lactamase- and AmpC β-lactamase-producing Enterobacterales associated with urinary tract infections in the New Zealand community: a case-control study.
    Toombs-Ruane LJ; Marshall JC; Benschop J; Drinković D; Midwinter AC; Biggs PJ; Grange Z; Baker MG; Douwes J; Roberts MG; French NP; Burgess SA
    Int J Infect Dis; 2023 Mar; 128():325-334. PubMed ID: 36529370
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidemiology and characteristics of urinary tract infections in children and adolescents.
    Hanna-Wakim RH; Ghanem ST; El Helou MW; Khafaja SA; Shaker RA; Hassan SA; Saad RK; Hedari CP; Khinkarly RW; Hajar FM; Bakhash M; El Karah D; Akel IS; Rajab MA; Khoury M; Dbaibo GS
    Front Cell Infect Microbiol; 2015; 5():45. PubMed ID: 26075187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in a medical center in Taiwan: a prospective cohort study.
    Kung CH; Ku WW; Lee CH; Fung CP; Kuo SC; Chen TL; Lee YT
    J Microbiol Immunol Infect; 2015 Apr; 48(2):168-74. PubMed ID: 24064292
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk factors for extended-spectrum β-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: a case-control study.
    Søgaard M; Heide-Jørgensen U; Vandenbroucke JP; Schønheyder HC; Vandenbroucke-Grauls CMJE
    Clin Microbiol Infect; 2017 Dec; 23(12):952-960. PubMed ID: 28377310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
    BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli show same antibiotic resistance when it recurs?
    Ahn ST; Kim SW; Kim JW; Park HS; Moon DG; Oh MM
    J Infect Chemother; 2019 Jul; 25(7):498-502. PubMed ID: 30852104
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ESBL-producing enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence.
    Pilmis B; Scemla A; Join-Lambert O; Mamzer MF; Lortholary O; Legendre C; Zahar JR
    Infect Dis (Lond); 2015; 47(10):714-8. PubMed ID: 26024285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
    O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
    BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.